Considerations on /sup 131/I-metaiodobenzylguanidine therapy of six children with neuroblastoma

Journal Article · Thu Jan 01 04:00:00 EST 1987 · Med. Pediatr. Oncol.; (United States)

DOI:https://doi.org/10.1002/mpo.2950150415· OSTI ID:5849338

Sanguineti, M

Six children affected by neuroblastoma at stages III and IV were treated with high-specific-activity /sup 131/I-metaiodobenzylguanidine (MIBG). After /sup 131/I-MIBG treatment three patients died at 12, 10, and 12 weeks, respectively; the other three were still living at 21, 16, and 24 weeks, respectively. Although the assumptions for this therapy were propitious, the results obtained do not correspond to those expected. It is supposed that large tumor volume and previous chemotherapy and/or radiotherapy may impair the effectiveness of /sup 131/I-MIBG therapy. Consequently, /sup 131/I-MIBG therapy is recommended even if the spread of disease is not proven-only, however, when the tumor is small.

• Research Organization: Nuclear Medicine Service, Genoa, Italy
• OSTI ID: 5849338
• Journal Information: Med. Pediatr. Oncol.; (United States), Journal Name: Med. Pediatr. Oncol.; (United States) Vol. 15:4; ISSN MPOND
• Country of Publication: United States
• Language: English

Related Subjects

550604* -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
AGE GROUPS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
CHILDREN
DAYS LIVING RADIOISOTOPES
DISEASES
DRUGS
INTERMEDIATE MASS NUCLEI
IODINE 131
IODINE ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
PATIENTS
RADIOISOTOPES
RADIOLOGY
RADIOPHARMACEUTICALS
RADIOTHERAPY
THERAPEUTIC USES
THERAPY
USES